The complete version of the Chinese instruction manual of Capmatinib (Touradda) and the main medication points

Capmatinib (Capmatinib) is an oral small molecule selective MET tyrosine kinase inhibitor, mainly used to treat patients with MET penetrance Non-small cell lung cancer (NSCLC) patients with sub-14 skip mutations (METex14). As a precise targeted drug, capmatinib can effectively inhibit the abnormal activation of the MET signaling pathway, thereby blocking tumor cell proliferation and metastasis. The following will provide a detailed analysis from four aspects: drug overview, indications, usage and dosage, adverse reactions and precautions, as well as drug interactions and clinical medication points.

1. Overview of Drugs

Capmatinib is a highly selective oral MET inhibitor. The chemical structure design can enhance the affinity to MET tyrosine kinase while reducing the inhibitory effect on other tyrosine kinases, thereby improving the safety and effectiveness of targeted therapy. The drug slows down the proliferation of tumor cells and induces apoptosis by inhibiting METkinase activity and blocking downstream signaling pathways such as PI3K/AKT and RAS/MAPK. In addition, capmatinib has high oral bioavailability and stable pharmacokinetics, making it convenient for long-term maintenance treatment.

2. Indications, usage and dosage

Capmatinib is suitable for adults with METex14 mutation-positive locally advanced or metastatic non-small cell lung cancer, especially when conventional chemotherapy or immunotherapy is ineffective. The recommended dose is 400mg, taken orally twice daily on an empty stomach. Swallow the tablet whole without chewing or crushing. During the treatment period, the dose should be adjusted according to the patient's liver and kidney function status and individual tolerance. If serious side effects occur, the dose can be appropriately reduced or the medication can be suspended and resumed under the guidance of a doctor. Treatment should be continued until disease progression or unacceptable toxicity occurs.

3. Adverse reactions and precautions

Clinical studies have shown that the adverse reactions of capmatinib mainly include edema, nausea, vomiting, fatigue, and increased serum creatine kinase. A small number of patients may develop pneumonia, interstitial lung disease, or severe liver function abnormalities. During the treatment process, blood routine, liver and kidney function and imaging indicators should be regularly monitored to detect abnormalities early and intervene promptly. If patients experience severe edema or difficulty breathing, they should seek medical treatment immediately and adjust the dose or suspend treatment under the guidance of a doctor. In addition, pregnant and lactating women should avoid the use of capmatinib, and male patients should use effective contraception during treatment.

4. Drug interactions and key points in clinical medication

Capmatinib is mainly metabolized by the liverCYP3A enzyme, and the combined use of potent CYP3A inhibitors (such as clarithromycin, ketoconazole) may lead to an increase in blood concentration and increase the risk of toxicity; the use of CYP3A inducers (such as rifampicin, carbamazepine) may reduce the efficacy. Therefore, potential interactions need to be evaluated before coadministration and dosage adjustments should be made accordingly. The key points of clinical medication include: insist on taking on an empty stomach, swallow the tablet whole, regularly monitor laboratory indicators, manage adverse reactions in a timely manner, and adjust dosage according to the guidance of a doctor. At the same time, patients should maintain a healthy lifestyle, including a balanced diet, regular work and rest, and moderate exercise to improve treatment tolerance and overall efficacy.

In summary, capmatinib, as a MET targeted inhibitor, provides a precise and effective treatment option for patients with METex14 mutation-positive non-small cell lung cancer. By strictly following the instructions, monitoring adverse drug reactions and paying attention to drug interactions, patients can maximize the efficacy while ensuring safety, which provides important support for personalized anti-tumor treatment.

Reference link:https://www.drugs.com